# Zenflow

**Canonical:** https://apis.io/providers/zenflow/  
**Website:** https://www.zenflow.com/  
**APIs profiled:** 0

Zenflow is a San Francisco-based medical device company founded in 2014 (Y Combinator W15) that develops the Zenflow Spring, a small permanent implant delivered in a minimally invasive in-office procedure to relieve urinary obstruction caused by benign prostatic hyperplasia (BPH). The company positions the Spring as a long-lasting alternative to daily BPH medications and to more invasive surgical procedures, avoiding their side effects and recovery burden. Zenflow is a medical-device / hardware company and does not publish a public API, developer platform, SDKs, MCP server, or webhooks; this record is maintained in the API Evangelist network as a company profile.

## Kin Score — 7.9 / 100 (minimal)

Scored 2026-08-21 under rubric 0.12.0. Trend: flat (+0.0 from 7.9).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 21.1 |
| Access Clarity | 21.1 |

Regulatory layer — **Health**: 10.0 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Tags

Company, Medical Devices, Healthcare, MedTech, Urology, Implant, Y Combinator

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/zenflow/). Scores are computed from the provider's own public artifacts under a published rubric.